Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06541652
Recruiting Observational

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

NCT06541652 · tracked via the Priya Life Science France tracker
Sponsor
Federation Francophone de Cancerologie Digestive
Phase
Observational
Started
2024-03-26
Last updated
2025-08-05

Condition(s) studied

HepatocholangiocarcinomaFibrolamellar CarcinomaHepatic Epithelioid HemangioendotheliomaHepatoblastomaHepatic Neuroendocrine CarcinomaHepatic CarcinosarcomasHepatic CystadenomaHepatic LeiomyosarcomasHepatic AngiosarcomasCholangiocarcinoma

Study summary

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years of age or older, * with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma * diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort * for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies. Exclusion Criteria: * without social security * No access to tumor block

Primary outcome measure(s)

  • Description of the clinical, histological and radiological characteristics of various rare primary liver cancers — up to 5 years from the date of diagnosis
    Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

Trial sites (40)

FacilityCityRegionStatus
CHU Amiens picardie Amiens France Recruiting
Chu Angers Angers France Recruiting
Ch - Centresimone Veil de Beauvais Beauvais France Recruiting
Chu Jean Minjoz Besançon France Not Yet Recruiting
Ch Bethune Beuvry Béthune France Not Yet Recruiting
Avicenne Bobigny France Recruiting
Cote de Nacre Caen France Not Yet Recruiting
Centre Hospitalier Calais France Recruiting
Chu de Clichy Hopital Beaujon Clichy France Recruiting
Centre Hospitalier Universitaire Henri Mondor Créteil France Recruiting
CHU Dijon France Recruiting
Chu Grenobles Alpes La Tronche France Recruiting
Centre Hospital Universitaire de lille Lille France Recruiting
Longjumeau Ch Nord Essone Longjumeau France Recruiting
Ch Edouard Herriot Lyon France Recruiting
Centre Léon Berard Lyon France Recruiting
La Clinique de La Sauvegarde Lyon France Recruiting
Chu Edouard Herriot Lyon France Recruiting
Lyon Cac Leon Berard Lyon France Recruiting
Lyon La Croix Rousse Lyon France Not Yet Recruiting
Hopital Saint Joseph Marseille France Recruiting
Chu de La Timone Marseille France Recruiting
CHR - Metz Thionville Hopital de Mercy Metz France Recruiting
CHU La Source Orléans France Not Yet Recruiting
Chu de Paris Saint Antoine Paris France Recruiting
AP - HP - Pitié Salpêtrière Paris France Recruiting
PAU CH Pau France Not Yet Recruiting
Centre Hospitalier de Perpignan Perpignan France Recruiting
Hopital Haut Leveque Pessac France Recruiting
Chu de Poitiers Poitiers France Recruiting
CH - Annecy Genevois Pringy France Recruiting
Chu Robert Debre Reims France Recruiting
CAC - Eugène Marquis Rennes France Not Yet Recruiting
Ico Site Rene Gauducheau Saint-Herblain France Not Yet Recruiting
Hopital Nord Chu Saint Etienne Saint-Priest-en-Jarez France Recruiting
Groupe Hospitalier Rance Emeraude St-Malo France Recruiting
Chu Rangueil Toulouse France Recruiting
Chru de Tours Tours France Not Yet Recruiting
Chu Paul Brousse Villejuif France Not Yet Recruiting
Gustave Roussy Villejuif France Not Yet Recruiting

More Federation Francophone de Cancerologie Digestive trials in France

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab Starting soon
Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer Recruiting
Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. Starting soon
Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer Recruiting
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer Starting soon

Other trials for the same condition

Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy Recruiting
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Active, not recruiting
Paediatric Hepatic International Tumour Trial Active, not recruiting
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting
Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06541652 on ClinicalTrials.gov ↗ ← All trials in France